Lantern Pharma Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$18.0M | -$22.2M | -$17.9M | -$14.4M | -$12.6M |
| Operating expenses | $18.0M | $22.2M | $17.9M | $14.4M | $12.6M |
| Cash from operations | -$15.7M | -$17.8M | -$14.3M | -$12.8M | -$10.6M |
| Capital expenditure | $1,715 | $12,595 | $18,734 | $27,844 | $15,499 |
| Free cash flow | -$15.7M | -$17.8M | -$14.4M | -$12.8M | -$10.6M |
| Share repurchases | — | — | $499,997 | $2.5M | $939,666 |
| Total assets | $11.0M | $25.6M | $43.6M | $58.8M | $74.0M |
| Total liabilities | $4.5M | $4.4M | $2.7M | $2.8M | $2.4M |
Shares outstanding 11.3M · Free float 77.0%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.